VRP 1620
Alternative Names: Endothelin - Venus Remedies; VRP1620Latest Information Update: 03 Oct 2016
At a glance
- Originator University of Illinois
- Developer Venus Remedies
- Class Imaging agents
- Mechanism of Action Endothelin B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer
Most Recent Events
- 19 Aug 2013 Phase-III clinical trials in Breast cancer (Diagnosis) in India (IV)
- 27 Apr 2011 Venus Remedies completes enrolment in its phase I/II trial for Breast cancer (diagnosis) in India (CTRI2009-091-001006)
- 14 Dec 2010 Phase-I/II clinical trials in Breast cancer (Diagnosis) in India (IV)